SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Biotechs >

Neurotrope Inc. (NTRP)

Add NTRP Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, Bob Stocks, runncoach, PatrickBateman, kld2
Search This Board: 
Last Post: 3/23/2017 9:37:49 PM - Followers: 55 - Board type: Free - Posts Today: 67

NTRPD Security Details
Share Structure

Market Value1 $45,774,160 a/o Jan 18, 2017
Authorized Shares 12,500,000 a/o Jan 12, 2017
Outstanding Shares 6,781,357 a/o Jan 12, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 1,627,372 a/o Jan 12, 2017


Top line Phase 2 study results expected to be released in April 2017The Company has also raised an additional $4.3 million in a final closing of its private placement for a total amount of $24.5 million


NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Neurotrope, Inc. (otcqb:NTRP), a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has initiated dosing in the final patient in its randomized, double-blinded, placebo-controlled, Phase 2 study in moderate to severe Alzheimer's disease patients.  The primary endpoint of the trial is the Severe Impairment Battery (SIB) and the secondary endpoints are the Mini Mental State Exam (MMSE), Activity of Daily Living (ADL) and Neuropsychiatric Inventory scale (NPI).  Top line results from the study are expected to be announced in April 2017.  Patients meeting the MMSE enrollment criteria score of 4-15 were enrolled in the study.  Two doses of bryostatin, 20ug and 40ug, vs. placebo for 12 weeks are being tested.  A total of 148 patients were enrolled into the study. 

The Company also announced that it has raised an additional $4.3 million in a final closing of its private placement in addition to the approximately $20.2 million raised and previously announced in a press release on Friday, November 18, 2016.

"Completion of enrollment in this study marks a significant milestone for Neurotrope, as well as the Alzheimer's community, as we take another step toward advancing what we believe could be the first potential new treatment for people with Alzheimer's disease in more than 15 years, and we believe would be the first one targeting causes of the symptoms, lost synaptic networks, and not just providing transient symptomatic relief," said Dr. Daniel Alkon, MD, Neurotrope's President and Chief Scientific Officer.  "Other companies targeting this disease are enrolling mildly impaired patients. We targeted the more severe patient population because of our experience with severe patients through our compassionate use studies. Those studies suggested reversal of some of the manifestations of the disease."

"Bryostatin's multi-modal mechanism of action not only targets the neuronal deficits of AD but also synaptic deficits.  This combined mechanism of action through PKC epsilon activation gave the Company the confidence to commit to these trials in moderate to severe patients," said Dr. Susanne Wilke, PhD., the Company's Chief Executive Officer.  "We believe that we may have a breakthrough in Alzheimer's disease and other neurological disorders. With the recently completed financing, we believe that we are in a strong position to negotiate terms with pharmaceutical partners."

Josh Silverman, Chairman of the Company, added, "We are pleased with the investor response to our new management team and the excitement surrounding our upcoming clinical data.  We raised more money than anticipated and plan on investing our capital efficiently in our continuing effort to increase shareholder value while making a difference in treating neurological disorders."

Further details may be found in the Company's Form 8-K filing with the Securities and Exchange Commission (SEC).

The securities to be sold in the private placement will not have been registered under the Securities Act of 1933, as amended, or state securities laws as of the time of issuance and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from such registration requirements.  Neurotrope has agreed to file one or more registration statements with the SEC registering the resale of the shares of common stock underlying the warrants purchased in the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Neurotrope         

Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes and a by bryostatin, a natural product, which in mouse AD models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.  

Neurotrope is also conducting preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome.  Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.

Neurotrope has exclusively licensed technology from Cognitive Research Enterprises (formerly named the Blanchette Rockefeller Neurosciences Institute) for Alzheimer's disease therapeutics and Fragile X Syndrome and has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C disease. 

Trial details 
NTRP Security Details
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NTRP News: Annual Report (10-k) 03/10/2017 04:36:46 PM
NTRP News: Current Report Filing (8-k) 02/24/2017 05:03:56 PM
NTRP News: Statement of Changes in Beneficial Ownership (4) 02/22/2017 05:03:45 PM
NTRP News: Initial Statement of Beneficial Ownership (3) 02/22/2017 05:02:51 PM
NTRP News: Current Report Filing (8-k) 02/22/2017 05:02:26 PM
#1870  Sticky Note NTRP has updated their Company presentation on their website: SF Wolf 03/14/17 08:33:06 AM
#710  Sticky Note Why I will be watching but not investing XenaLives 02/14/17 10:51:33 AM
#679  Sticky Note February 13 conference...includes results from compassionate use patients runncoach 02/13/17 03:30:18 PM
#2481   With all due respect how do you think doingmybest 03/23/17 09:37:49 PM
#2480   kid2: "2 or 3 CU patients could demonstrate that InTheTrenches 03/23/17 09:05:29 PM
#2479   You should listen to the Openhiemer audio. Whatsupp 03/23/17 08:44:50 PM
#2478   One basic question - even if synaptic networks Amatuer17 03/23/17 08:25:02 PM
#2477   Good write up. Agree on most points - look Amatuer17 03/23/17 08:19:09 PM
#2476   I don't really put a percentage on it runncoach 03/23/17 07:09:00 PM
#2475   Yes and Professor Tanzi's approach was eliminating plaques. Whatsupp 03/23/17 06:57:14 PM
#2474   What was the approach of PRANA? Theburg 03/23/17 06:20:10 PM
#2473   Here's the reason I give this trial an Theburg 03/23/17 06:17:48 PM
#2472   Everybody likes to quote Dr. Alkon and his kld2 03/23/17 06:02:03 PM
#2471   antti, one more thing. I could be wrong kld2 03/23/17 05:39:50 PM
#2470   My understanding is it was the 95-year-old patient InTheTrenches 03/23/17 05:30:07 PM
#2469   Simple: statistics. The bigger the number the smaller kld2 03/23/17 05:25:09 PM
#2468   Boy are you jumping all over the place. Whatsupp 03/23/17 05:24:35 PM
#2467   What Dr Alkon was talking about Tuesday was runncoach 03/23/17 05:11:31 PM
#2466   Even though you weren't asking me to answer Antti 03/23/17 05:08:34 PM
#2465   As an investor, one uses ALL sources of frontiers 03/23/17 05:05:33 PM
#2464   So how does that work? A press release kld2 03/23/17 04:57:20 PM
#2462   I agree that the effect that Bryo had frontiers 03/23/17 03:56:15 PM
#2461   Everyone decides what's best for themselves and that's fine. Antti 03/23/17 03:35:50 PM
#2459   Does it really have to be this hard? kld2 03/23/17 03:09:15 PM
#2458   This is the summary of the 2a trial runncoach 03/23/17 02:51:50 PM
#2457   Dr Alkon clearly said at the 22 minute Whatsupp 03/23/17 02:50:40 PM
#2456   sorry, red, I am long both. kld2 03/23/17 02:44:58 PM
#2455   In fact, it's much worse. So far 99.6% kld2 03/23/17 02:39:19 PM
#2454   I believe it was March 2015 pr. Look kld2 03/23/17 02:37:11 PM
#2453   I think the poster's reference is to an donsker 03/23/17 02:16:45 PM
#2452   "There is A LOT to criticize bryostatin and F1ash 03/23/17 02:14:43 PM
#2451   There are obviously two sides to the risk/return doingmybest 03/23/17 02:04:23 PM
#2450   Hey,kid since you assign 100% chance of ntrp reddyramana 03/23/17 01:20:36 PM
#2449   OK, if I go with your estimate of frontiers 03/23/17 12:42:52 PM
#2448   Lol. Well, I believe you may F1ash 03/23/17 12:00:57 PM
#2447   "Don't have any human clinical data on efficacy. Whatsupp 03/23/17 11:52:21 AM
#2446   Should happen soon Maple tree 03/23/17 11:35:58 AM
#2445   Whether the success ratio is 80%, 50% or donsker 03/23/17 11:35:40 AM
#2444   NTRP Any updates on Naz listing? bUrRpPPP! 03/23/17 11:31:34 AM
#2443   Don't have any human clinical data on efficacy. kld2 03/23/17 11:21:59 AM
#2442   hot board is unfair to say ntrp reddyramana 03/23/17 11:12:21 AM
#2441   -------------------------- 80% chance? Yah, right. it's worth a bet, Antti 03/23/17 11:06:52 AM
#2440   But still, what percent of the failed trials Theburg 03/23/17 11:00:13 AM
#2439   80% chance? Yah, right. it's worth a bet, kld2 03/23/17 10:50:32 AM
#2438   The epileptologist told me patients with severe Alzheimers GentleGiant123 03/23/17 10:17:42 AM
#2437   blu1- very interesting post. can you tell us GentleGiant123 03/23/17 10:14:24 AM
#2436   I don't think NTRP's approach is grasping in Theburg 03/23/17 10:12:41 AM
#2435   What percent of that 91% of the trials Theburg 03/23/17 10:06:45 AM
#2432   That is easy, massive dilution from LPC. Whatsupp 03/23/17 09:41:08 AM
#2431   ------------------------- Why a 3 month Ph 3 trial Antti Antti 03/23/17 09:22:58 AM
#2430   Can you give the link to your article? InTheTrenches 03/23/17 09:21:59 AM
#2429   Antti, excellent post with the real bottom line doingmybest 03/23/17 09:16:27 AM
#2428   Antti, excellent post with the real bottom line doingmybest 03/23/17 09:16:26 AM